• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The third generation cephalosporins.

作者信息

Farber B, Moellering R C

出版信息

Bull N Y Acad Med. 1982 Nov;58(8):696-710.

PMID:6762896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1805373/
Abstract
摘要

相似文献

1
The third generation cephalosporins.第三代头孢菌素。
Bull N Y Acad Med. 1982 Nov;58(8):696-710.
2
Choice of cephalosporins.头孢菌素的选择。
Med Lett Drugs Ther. 1983 Jun 10;25(637):57-60.
3
Clinical pharmacology of cephalosporin antibiotics.
J Am Vet Med Assoc. 1984 Feb 1;184(3):344-7.
4
[Antibiotics and chemotherapeutic agents--from research to practice. X. Various comments intended for practitioners on the properties of cephalosporins].
Schweiz Arch Tierheilkd. 1984 Apr;126(4):173-87.
5
[20 years of cephalosporins].[头孢菌素类药物的20年]
Ned Tijdschr Geneeskd. 1985 Feb 23;129(8):342-6.
6
[Third generation cephalosporins: 2 sides of the coin].[第三代头孢菌素：硬币的两面]
Salud Publica Mex. 1985 Nov-Dec;27(6):479-84.
7
Cefepime: part of the new generation.头孢吡肟：新一代的一部分。
Am J Hosp Pharm. 1994 Feb 15;51(4):459-60.
8
[The cephalosporins. I].[头孢菌素。I]
Clin Ter. 1978 Jan 31;84(2):167-93.
9
[General considerations on the clinical use of cephalosporins].[头孢菌素临床应用的一般考虑]
Minerva Pediatr. 1977 Feb 4;29(3):183-214.
10
[Old and new cephalosporins. Pharmacologic and clinical considerations].
Clin Ter. 1985 Jan 15;112(1):45-65.

引用本文的文献

1
ESBL-producing 
and Its Rapid Rise among Healthy People.产超广谱β-内酰胺酶及其在健康人群中的迅速增加。
Food Saf (Tokyo). 2017 Dec 29;5(4):122-150. doi: 10.14252/foodsafetyfscj.2017011. eCollection 2017 Dec.
2
Current status of antibiotic prophylaxis in surgical patients.外科患者抗生素预防的现状
Bull N Y Acad Med. 1984 May;60(4):340-57.

本文引用的文献

1
Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin.临床分离细菌对头孢西丁和头孢噻吩的敏感性。
Antimicrob Agents Chemother. 1974 Sep;6(3):320-3. doi: 10.1128/AAC.6.3.320.
2
In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic.新型β-内酰胺抗生素1-氧杂头孢菌素（LY 127935）的体外研究
Antimicrob Agents Chemother. 1980 Jan;17(1):92-5. doi: 10.1128/AAC.17.1.92.
3
Cefaclor and cefadroxil: a commentary on their properties and possible indications for use in pediatrics.
J Pediatr. 1980 Feb;96(2):340-2. doi: 10.1016/s0022-3476(80)80843-2.
4
Evaluation of ceforanide as treatment for staphylococcal and streptococcal endocarditis.头孢乙腈作为葡萄球菌和链球菌性心内膜炎治疗药物的评估。
Antimicrob Agents Chemother. 1981 Feb;19(2):256-9. doi: 10.1128/AAC.19.2.256.
5
Intraventricular use of aminoglycosides in the treatment of gram-negative bacillary meningitis: conflicting views.氨基糖苷类药物脑室内给药治疗革兰阴性杆菌脑膜炎：观点不一。
J Infect Dis. 1981 Feb;143(2):293-6. doi: 10.1093/infdis/143.2.293.
6
Considerations regarding clinical safety and tolerability of antibiotics in serious and nosocomial infections.
Clin Ther. 1981;4 Suppl A:133-45.
7
Cephalosporins.
Annu Rev Med. 1981;32:559-81. doi: 10.1146/annurev.me.32.020181.003015.
8
Binding of beta-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity.β-内酰胺类抗生素与金黄色葡萄球菌和粪肠球菌青霉素结合蛋白的结合：与抗菌活性的关系。
Antimicrob Agents Chemother. 1980 Nov;18(5):834-6. doi: 10.1128/AAC.18.5.834.
9
Penetration of moxalactam into its target proteins in Escherichia coli K-12: comparison of a highly moxalactam resistant mutant with its parent strain.莫西拉酸在大肠杆菌K-12中对其靶蛋白的渗透：高耐莫西拉酸突变体与其亲本菌株的比较。
Antimicrob Agents Chemother. 1981 Nov;20(5):613-9. doi: 10.1128/AAC.20.5.613.
10
beta-Lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment.在囊性纤维化治疗期间出现的具有修饰青霉素结合蛋白的β-内酰胺耐药铜绿假单胞菌。
Antimicrob Agents Chemother. 1981 May;19(5):705-11. doi: 10.1128/AAC.19.5.705.